These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27836099)

  • 1. [Management of cardiogenic shock: Results from a survey in France and Belgium].
    Champion S; Deye N
    Ann Cardiol Angeiol (Paris); 2017 Apr; 66(2):59-65. PubMed ID: 27836099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic support in cardiogenic shock.
    Rude RE
    Adv Shock Res; 1983; 10():35-49. PubMed ID: 6349299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of Levosimendan on global haemodynamics in patients with cardiogenic shock.
    Rokyta R; Pechman V
    Neuro Endocrinol Lett; 2006; 27(1-2):121-7. PubMed ID: 16648778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study.
    Levy B; Perez P; Perny J; Thivilier C; Gerard A
    Crit Care Med; 2011 Mar; 39(3):450-5. PubMed ID: 21037469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of survival in unselected patients with acute myocardial infarction requiring continuous catecholamine support.
    Schreiber W; Herkner H; Koreny M; Bur A; Hirschl MM; Glogar D; Huber K; Laggner AN
    Resuscitation; 2002 Dec; 55(3):269-76. PubMed ID: 12458064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inotropic therapy for cardiac low output syndrome: comparison of hemodynamic effects of dopamine/dobutamine versus dopamine/dopexamine.
    El Mokhtari NE; Arlt A; Meissner A; Lins M
    Eur J Med Res; 2007 Nov; 12(11):563-7. PubMed ID: 18024265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inotropic agents in the treatment of cardiogenic shock.
    Bourdarias JP; Dubourg O; Gueret P; Ferrier A; Bardet J
    Pharmacol Ther; 1983; 22(1):53-79. PubMed ID: 6361798
    [No Abstract]   [Full Text] [Related]  

  • 8. Recommendations for the treatment of patients with septic shock.
    Meier-Hellmann A; Reinhart K
    Acta Anaesthesiol Scand Suppl; 1997; 111():177-80. PubMed ID: 9421002
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics.
    García-González MJ; Domínguez-Rodríguez A; Ferrer-Hita JJ; Abreu-González P; Muñoz MB
    Eur J Heart Fail; 2006 Nov; 8(7):723-8. PubMed ID: 16492404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Essential lessons in cardiogenic shock: epinephrine versus norepinephrine/dobutamine.
    Krenn L; Delle Karth G
    Crit Care Med; 2011 Mar; 39(3):583-4. PubMed ID: 21330855
    [No Abstract]   [Full Text] [Related]  

  • 11. Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
    Mathew R; Di Santo P; Jung RG; Marbach JA; Hutson J; Simard T; Ramirez FD; Harnett DT; Merdad A; Almufleh A; Weng W; Abdel-Razek O; Fernando SM; Kyeremanteng K; Bernick J; Wells GA; Chan V; Froeschl M; Labinaz M; Le May MR; Russo JJ; Hibbert B
    N Engl J Med; 2021 Aug; 385(6):516-525. PubMed ID: 34347952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network Meta-Analysis of the Safety of Drug Therapy for Cardiogenic Shock.
    Liao X; Qian L; Zhang S; Chen X; Lei J
    J Healthc Eng; 2020; 2020():8862256. PubMed ID: 32802302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extensive variability in vasoactive agent therapy: a nationwide survey in Chinese intensive care units.
    Pei XB; Ma PL; Li JG; Du ZH; Zhou Q; Lu ZH; Yun L; Hu B
    Chin Med J (Engl); 2015 Apr; 128(8):1014-20. PubMed ID: 25881592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality.
    Tarvasmäki T; Lassus J; Varpula M; Sionis A; Sund R; Køber L; Spinar J; Parissis J; Banaszewski M; Silva Cardoso J; Carubelli V; Di Somma S; Mebazaa A; Harjola VP;
    Crit Care; 2016 Jul; 20(1):208. PubMed ID: 27374027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction.
    Levy B; Clere-Jehl R; Legras A; Morichau-Beauchant T; Leone M; Frederique G; Quenot JP; Kimmoun A; Cariou A; Lassus J; Harjola VP; Meziani F; Louis G; Rossignol P; Duarte K; Girerd N; Mebazaa A; Vignon P;
    J Am Coll Cardiol; 2018 Jul; 72(2):173-182. PubMed ID: 29976291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of medical management of cardiogenic shock in the era of mechanical circulatory support.
    Blumer V; Marbach J; Veasey T; Kanwar M
    Curr Opin Cardiol; 2022 May; 37(3):250-260. PubMed ID: 35612937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of haemodynamic responses to dobutamine and salbutamol in cardiogenic shock after acute myocardial infarction.
    Fowler MB; Timmis AD; Crick JP; Vincent R; Chamberlain DA
    Br Med J (Clin Res Ed); 1982 Jan; 284(6309):73-6. PubMed ID: 6797661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of vasopressors and inotropics in cardiogenic shock].
    Lemm H; Dietz S; Janusch M; Buerke M
    Herz; 2017 Feb; 42(1):3-10. PubMed ID: 28101622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiogenic shock.
    Rackley CE; Russell RO; Mantle JA; Rogers WJ
    Cardiovasc Clin; 1981; 11(3):15-24. PubMed ID: 7214388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The medical treatment of cardiogenic shock: cardiovascular drugs.
    De Backer D; Arias Ortiz J; Levy B
    Curr Opin Crit Care; 2021 Aug; 27(4):426-432. PubMed ID: 33797431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.